MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

17-214-09 CA045002

PIVOT9

Protocol Title

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma

17777 1841788 ARASENS A Randomized, Double–Blind, Placebo–Controlled Phase III Study of Darolutamide (ODM–201) versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients with Metastatic Hormone–Sensitive Prostate Cancer

18-214-10 CA045-012

PIVOT-10

A Phase 2, Randomized, Non-Comparative, Open-Label Study of NKTR-214 in Combination with Nivolumab and of Chemotherapy in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients with Low PD-L1 Expression

2019-013-GLOB1

FRESCO-2

A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib plus Best Supportive Care to Placebo plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer

20321 Darolutamide ROS An Open-Label, Single Arm, Roll-Over Study to Provide Continued Treatment with Darolutamide in Participants who Were Enrolled in Previous Bayer-Sponsored Studies

2125-MEL-301 Illuminate-301

213410 COSTAR Lung

A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with PD 1 Refractory Melanoma

A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants with Advanced Nonsmall Cell Lung Cancer who Have Progressed On Prior Anti-Pd-(L)1 Therapy and Chemotherapy

42756493CAN2002 Ragnar A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumours and FGFR Gene Alterations

56021927PCR3001 ACIS A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

64091742PCR0002 PREVALENCE

Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer